|
Report No. : |
353780 |
|
Report Date : |
16.12.2015 |
IDENTIFICATION DETAILS
|
Name : |
AMNEAL PHARMACEUTICALS OF NEW YORK LLC |
|
|
|
|
Registered Office : |
85 Adams Avenue, Hauppauge, NY 11788 |
|
|
|
|
Country : |
United States |
|
|
|
|
Date of Incorporation : |
14.04.2008 |
|
|
|
|
Legal Form : |
LLC |
|
|
|
|
Line of Business : |
· Develops, manufactures, and distributes generic pharmaceuticals in the United States. · The company’s portfolio includes controlled substances, hormonal products, high potency formulations, soft gelatin capsules, tablets, liquids, oral solids, and ophthalmic category products. |
|
|
|
|
No. of Employees : |
245 (For the Group) |
RATING & COMMENTS
|
MIRA’s Rating : |
Ba |
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
Status : |
Satisfactory |
|
|
|
|
Payment Behaviour : |
Slow but correct |
|
|
|
|
Litigation : |
Exist |
NOTES:
Any query related to this report can be made
on e-mail: infodept@mirainform.com
while quoting report number, name and date.
ECGC Country Risk Classification List – March 31, 2015
|
Country Name |
Previous Rating (31.12.2014) |
Current Rating (31.03.2015) |
|
United States |
A1 |
A1 |
|
Risk Category |
ECGC
Classification |
|
Insignificant |
A1 |
|
Low |
A2 |
|
Moderate |
B1 |
|
High |
B2 |
|
Very High |
C1 |
|
Restricted |
C2 |
|
Off-credit |
D |
UNITED STATES - ECONOMIC
OVERVIEW
The US has the most
technologically powerful economy in the world, with a per capita GDP of $54,800.
US firms are at or near the forefront in technological advances, especially in
computers, pharmaceuticals, and medical, aerospace, and military equipment;
however, their advantage has narrowed since the end of World War II. Based on a
comparison of GDP measured at Purchasing Power Parity conversion rates, the US
economy in 2014, having stood as the largest in the world for more than a
century, slipped into second place behind China, which has more than tripled
the US growth rate for each year of the past four decades.
In the US, private
individuals and business firms make most of the decisions, and the federal and
state governments buy needed goods and services predominantly in the private
marketplace. US business firms enjoy greater flexibility than their
counterparts in Western Europe and Japan in decisions to expand capital plant,
to lay off surplus workers, and to develop new products. At the same time, they
face higher barriers to enter their rivals' home markets than foreign firms
face entering US markets.
Long-term problems
for the US include stagnation of wages for lower-income families, inadequate
investment in deteriorating infrastructure, rapidly rising medical and pension
costs of an aging population, energy shortages, and sizable current account and
budget deficits.
The onrush of
technology has been a driving factor in the gradual development of a
"two-tier" labor market in which those at the bottom lack the
education and the professional/technical skills of those at the top and, more and
more, fail to get comparable pay raises, health insurance coverage, and other
benefits. But the globalization of trade, and especially the rise of low-wage
producers such as China, has put additional downward pressure on wages and
upward pressure on the return to capital. Since 1975, practically all the gains
in household income have gone to the top 20% of households. Since 1996,
dividends and capital gains have grown faster than wages or any other category
of after-tax income.
Imported oil
accounts for nearly 55% of US consumption and oil has a major impact on the
overall health of the economy. Crude oil prices doubled between 2001 and 2006,
the year home prices peaked; higher gasoline prices ate into consumers' budgets
and many individuals fell behind in their mortgage payments. Oil prices climbed
another 50% between 2006 and 2008, and bank foreclosures more than doubled in
the same period. Besides dampening the housing market, soaring oil prices
caused a drop in the value of the dollar and a deterioration in the US
merchandise trade deficit, which peaked at $840 billion in 2008.
The sub-prime
mortgage crisis, falling home prices, investment bank failures, tight credit,
and the global economic downturn pushed the United States into a recession by
mid-2008. GDP contracted until the third quarter of 2009, making this the
deepest and longest downturn since the Great Depression. To help stabilize
financial markets, the US Congress established a $700 billion Troubled Asset
Relief Program (TARP) in October 2008. The government used some of these funds
to purchase equity in US banks and industrial corporations, much of which had
been returned to the government by early 2011. In January 2009 the US Congress
passed and President Barack OBAMA signed a bill providing an additional $787
billion fiscal stimulus to be used over 10 years - two-thirds on additional
spending and one-third on tax cuts - to create jobs and to help the economy
recover. In 2010 and 2011, the federal budget deficit reached nearly 9% of GDP.
In 2012, the federal government reduced the growth of spending and the deficit
shrank to 7.6% of GDP. US revenues from taxes and other sources are lower, as a
percentage of GDP, than those of most other countries.
Wars in Iraq and
Afghanistan required major shifts in national resources from civilian to
military purposes and contributed to the growth of the budget deficit and
public debt. Through 2014, the direct costs of the wars totaled more than $1.5
trillion, according to US Government figures.
In March 2010,
President OBAMA signed into law the Patient Protection and Affordable Care Act,
a health insurance reform that was designed to extend coverage to an additional
32 million American citizens by 2016, through private health insurance for the
general population and Medicaid for the impoverished. Total spending on health
care - public plus private - rose from 9.0% of GDP in 1980 to 17.9% in 2010.
In July 2010, the
president signed the DODD-FRANK Wall Street Reform and Consumer Protection Act,
a law designed to promote financial stability by protecting consumers from
financial abuses, ending taxpayer bailouts of financial firms, dealing with
troubled banks that are "too big to fail," and improving
accountability and transparency in the financial system - in particular, by
requiring certain financial derivatives to be traded in markets that are
subject to government regulation and oversight.
In December 2012,
the Federal Reserve Board (Fed) announced plans to purchase $85 billion per
month of mortgage-backed and Treasury securities in an effort to hold down
long-term interest rates, and to keep short term rates near zero until
unemployment dropped below 6.5% or inflation rose above 2.5%. In late 2013, the
Fed announced that it would begin scaling back long-term bond purchases to $75
billion per month in January 2014 and reduce them further as conditions
warranted; the Fed ended the purchases during the summer of 2014. In 2014, the
unemployment rate dropped to 6.2%, and continued to fall to 5.5% by mid-2015, the
lowest rate of joblessness since before the global recession began; inflation
stood at 1.7%, and public debt as a share of GDP continued to decline,
following several years of increase.
|
Source
: CIA |
Company name: AMNEAL PHARMACEUTICALS OF NEW YORK LLC
Address: 85 Adams Avenue,
Hauppauge, NY 11788 - USA
Telephone: +1
631-952-0214
Fax: +1 631-656-1009
Website: www.amneal.com
Corporate ID#: 4533207
State: Delaware
Judicial form: LLC
Date incorporated: 04-14-2008
Stock: -
Value: -
Name of manager: Chintu
PATEL
Business:
Amneal Pharmaceuticals of New York, L.L.C. develops, manufactures, and
distributes generic pharmaceuticals in the United States.
The company’s portfolio includes controlled substances, hormonal
products, high potency formulations, soft gelatin capsules, tablets, liquids,
oral solids, and ophthalmic category products.
The company was founded in 2008 and is based in Hauppauge, NY.
Office
of the Foreign Assets Control (OFAC):
The company is not listed on the OFAC list.
The Specially Designated Nationals (SDN) List is a publication of OFAC
which lists individuals and organizations with whom United States citizens and
permanent residents are prohibited from doing business.
Suppliers include:
Sashun Pharmaceuticals Ltd
28, Sardar Patel Road, Guindy, Chennai 600032, Tamil Nadu, India
EIN: 90-0186021
Staff: 245 (for the group)
Operations & branches:
At above address, we find the New York administrative office.
The Business Development and corporate office is located:
440 US Highway 22 East, Ste 104, Bridgewater, NJ 08807 – USA
Ph: +1 908-947-3120
Fx: +1 908-947-4146
The Company maintains research and development facilities in Paterson,
Branchburg, and Piscataway, New Jersey; Long Island, New York; and Gujarat,
India, as well as a distribution center in Glasgow, Kentucky.
Shareholders:
Amneal Pharmaceuticals LLC
85 Adams Avenue, Hauppauge, NY 11788
Incorporated in Delaware on 06-5-2004
ID# 3809030
Management:
Chintu PATEL, co-Chairman and CEO
Chintu Patel, RPh, Co-founded Amneal Pharmaceuticals, L.L.C., heading up
research and development operations, quality management, manufacturing,
regulatory affairs and intellectual property in 2002 and serves as its Chief Executive
Officer and Co-chairman. Mr. Patel worked at Sidmak Laboratories in various
positions. He was a Pharmacist and served as a Manager with Eckerd Drugs. His
leadership has marshaled the successful application and approval of all ANDAs,
ensuring a 100% success rate of scale-up from lab to production quantities. Mr.
Patel started his pharmacy career in 1994.
He serves as a Co-Chairman at Amneal Enterprises, LLC. He received
numerous awards at Eckerd Drugs until his departure in 2002. He received his Bachelors
in Pharmacy from Rutgers College of Pharmacy.
Chirag PATEL, co-Chairman and President
Chirag Patel Co-founded Amneal Pharmaceuticals L.L.C. in 2002 and serves
as
its President and Co-chairman.
Mr. Patel Co-founded and serves as President and Chief Executive Officer
of Hotel Net Llc. Mr. Patel has more than 17 years experience in Information
Technology and its applications as well as in finance and management.
He Co-founded Veriprise Wireless Corporation in 1999, which extends
corporate applications to its mobile employees via handheld devices. He worked
with the Motorola global teams to jointly penetrate the markets in South
America and India. He Co-owned NextGen Technologies, where he managed its
strategy, business development and finance. Prior to forming Veriprise and
NextGen, Mr. Patel worked at Unisys Corporation, Terex Corporation (Clark
Manufacturing Division) and York International over the course of nine years,
in a variety of analytical, managerial and executive positions. He serves as
Co-chairman of Amneal Enterprises, LLC. He served as a Director of Superclick
Inc. since September 1, 2005. He served as a Director of Grand Prix Sports Inc.
He received a Bachelor's degree in Business Administration and Accounting from
Gujarat University India (1986) and New Jersey City University (1989) and has
qualified for C.P.A Certification in 1993.
Sanjiv PATEL, Sr. Vice President of
Operations
They are involved in:
Amneal Pharmaceuticals LLC
85 Adams Avenue, Hauppauge, NY 11788
Amneal
Pharmaceuticals Co. India Private Limited
882/1-871 Village Rajoda
Tal.:Bavla Dist.: Ahmedabad-382220, Gujarat, India
and others.
In United States, privately
held corporations are not required to publish any financials.
On a direct call, a
financial assistant controlled the present report.
Consolidate US sales
declared for year 2014 is in the range of
USD 350,000,000=
The business is said to be
profitable.
Banks: PNC Bank
Legal filings & complaints:
As of today date, there are more than 20 legal filing pending with the
Courts.
Secured debts summary (UCC):
Several in New York and New Jersey